10-K: BioNexus Gene Lab Corp. Reports Fiscal Year 2024 Results, Navigates Nasdaq Compliance, and Expands into Digital Health

BioNexus Gene Lab Corp. announces its fiscal year 2024 results, highlighting a strong liquidity position, strategic innovation initiatives, and proactive governance enhancements while addressing Nasdaq compliance challenges.

Summary

• BioNexus Gene Lab Corp. (BGLC) reported its fiscal year 2024 results, showcasing progress in core business operations and strategic initiatives.
• The company ended 2024 with approximately $4.37 million in cash and minimal debt, positioning it for strategic growth and technology investments.
• BGLC proactively embraced digital health technology, advanced molecular diagnostics, and blockchain-based treasury management.
• The company addressed Nasdaq compliance challenges, including implementing a strategic reverse stock split, to maintain its listing.
• BGLC anticipates continued strategic expansion into high-growth sectors, driven by robust corporate governance and innovative technologies.
• The company's subsidiary, Chemrex, focuses on the sale of chemical raw materials in Southeast Asia, while MRNA Scientific is developing non-invasive liquid biopsy tests for early disease detection.
• In July 2023, the company closed an initial public offering (IPO) at $4.00 per share, raising gross proceeds of $5.75 million.
• A 1-for-10 reverse stock split became market effective on April 7, 2025, to regain compliance with Nasdaq's minimum bid price rule.
• The company is working to improve corporate governance standards at its Chemrex subsidiary following the discovery of lapses in 2024.
• The company's new Ethereum-focused treasury strategy aligns BGLC with a transformational global financial infrastructure.

Sentiment

Score: 6

Explanation: The document presents a mixed sentiment. While the company highlights its strong liquidity position and strategic initiatives, it also acknowledges challenges such as Nasdaq compliance issues, internal control deficiencies, and a net loss for the year. The proactive approach to addressing these challenges and the focus on future growth contribute to a moderately positive outlook.

Positives

• The company has a strong cash position of approximately $4.37 million and minimal debt.
• BGLC is proactively expanding into high-growth sectors, including digital health and blockchain.
• The company is taking steps to improve corporate governance standards at its Chemrex subsidiary.
• The company's new Ethereum-focused treasury strategy aligns BGLC with a transformational global financial infrastructure.
• The company has secured a temporary exception to regain compliance with Nasdaq Listing Rule 5550(a)(2).

Negatives

• The company experienced a net loss of $1,598,342 for the year ended December 31, 2024.
• The company's disclosure controls and procedures were not effective as of December 31, 2024, due to a significant deficiency in internal control over financial reporting.
• The company received a Nasdaq delisting notification due to failure to comply with the minimum bid price rule.
• The company discovered lapses in corporate governance standards at its Chemrex subsidiary.
• The company experienced a revenue decrease of approximately 2.7% compared to the previous year.

Risks

• The company's risk management programs may not be adequate or effectively applied.
• Changes in laws and regulations could adversely impact the company's business.
• Business disruptions could seriously harm the company's future revenue and financial condition.
• The company may be unable to attract and retain key senior management members and research and development personnel.
• The company may be unable to protect its intellectual property adequately.
• The company may be subject to intellectual property claims.
• The company may face competition from other biotechnology competitors.
• Cyber breaches, loss of data, and other disruptions could compromise sensitive information.
• The company's plans to expand its tests and services to multiple countries exposes it to risks associated with doing business outside of Malaysia.
• The chemical raw material industry is cyclical and both recessions and prolonged periods of slow economic growth could have an adverse effect on Chemrexs business.
• The results of Chemrexs operations are sensitive to volatility in the cost of raw materials, particularly fibre reinforced plastics.
• Disruptions in the supply of chemicals that we distribute or in the operations of our customers could adversely affect our business.
• We have oral contracts with suppliers and customers, which are generally terminable upon notice, and the termination of our relationships with suppliers and customers contracts could negatively affect our business.
• We may lose customers and suffer damage to our reputation if we are unable to meet customer demand for a particular product.
• We may be exposed to product returns and product liability claims and latent defect liability claims.
• Our officers and directors may in future have outside business activities.
• Risk related to Nasdaq compliance due to board changes.
• Audit Committee investigation may result in material adjustments or restatements.
• Internal control deficiencies may persist despite remediation efforts.
• We may face shareholder rejection of unratified transactions.
• We may pursue collaborations, in-licensing or out-license arrangements, joint ventures, strategic alliances, partnerships or other strategic investments or arrangements, which may fail to produce anticipated benefits and adversely affect the companys operations.
• Changes in policies in Malaysia and other Southeast Asian countries could have a significant impact upon the companys ability to operate profitably in Malaysia and the Southeast Asia region.
• Developments in the social, political, regulatory and economic environment in Malaysia may have a material adverse impact on us.
• You may experience difficulties in effecting service of legal process, enforcing foreign judgments or bringing actions in Malaysia against the company or its management based on foreign laws, and the ability of U.S. authorities to bring actions in Malaysia may also be limited.
• We are subject to foreign exchange control policies in Malaysia.
• Volatility in our shares price may subject us to securities litigation.
• We may never be able to pay dividends and are unlikely to do so.
• Shareholders may be diluted significantly through our efforts to obtain financing and satisfy obligations through the issuance of securities.
• We are a smaller reporting company, and we cannot be certain if the reduced disclosure requirements applicable to smaller reporting companies will make our common stock less attractive to investors.

Future Outlook

BGLC anticipates continued strategic expansion into high-growth sectors, driven by robust corporate governance, innovative technologies, and sustained financial resilience. The company is exploring additional capital-raising mechanisms and intends to capitalize on its clean balance sheet to pursue selective mergers, acquisitions, and joint ventures.

Management Comments

• The Company is focused on active expansion of our business through both organic and inorganic means, and has retained industry leading support to support our financial growth and capital raising efforts.
• We are confident our actions will translate into sustainable shareholder value and long-term strategic advantages.

Industry Context

The company's expansion into digital health and blockchain-based treasury solutions aligns with broader industry trends towards technological innovation and decentralized finance. The company's focus on early disease detection through liquid biopsy screenings addresses a growing need for proactive health management.

Comparison to Industry Standards

• The composite raw materials market is expected to reach an estimated $40.2 billion by 2024 globally and is forecasted to grow at a CAGR of 3.3% from 2019 to 2024.
• The composites end-user market is expected to reach an estimated $114.7 billion by 2024 globally.
• Malaysia's industrial chemical market size is approximately USD 50 million per annum, and our current market share is around 20% of the domestic market.
• The market size of the Southeast Asian market is USD 500 million per annum, and our current market share is around 2.0% of the Southeast Asian market.
• Some prevalent cancer cases in Malaysia from Globocan 2020 endorsed by WHO Cancer screening costs from a diagnostic center is priced at $882 (RM3,880) as compared to MRNA screening at $432 (RM1,900), quantity genechip purchase would drastically reduce the screening cost.

Management Changes

Corporate Governance

Legal Proceedings

• We are not subjected to nor engaged in any litigation, arbitration, or claim of material importance, and no litigation, arbitration, or claim of material importance is known to us to be pending or threatened by or against our Company that would have a material adverse effect on our Company's results of operations or financial condition.

Related Party Transactions

• Sales to Honkuk Material Sdn. Bhd., a company affiliated with directors of Chemrex, were $34,060 in 2024 and $29,714 in 2023.
• Purchases from Honkuk Material Sdn. Bhd. were $288,767 in 2024 and $168,952 in 2023.
• Sales to RP Products Sdn. Bhd., an entity controlled by a Chemrex director, were $78,496 in 2024 and $77,205 in 2023.
• Purchases from RP Products Sdn. Bhd. were $8,969 in 2024 and $15,481 in 2023.
• Director remuneration (Chemrex and Holding Company) totaled $2,378,468 in 2024 and $461,254 in 2023.

Stakeholder Impact

• Shareholders: The company's efforts to maintain its Nasdaq listing and improve corporate governance are aimed at enhancing shareholder value.
• Employees: The company's expansion into new markets and technologies may create new opportunities for employees.
• Customers: The company's focus on innovation and quality control is intended to provide customers with better products and services.
• Suppliers: The company's relationships with its suppliers are important for ensuring a stable supply of raw materials.
• Creditors: The company's strong liquidity position and minimal debt reduce the risk for creditors.

Next Steps

• Full remediation of internal control deficiencies and establishment of a uniform group-level risk and compliance framework.
• Continued expansion into digital healthcare markets, including the deployment of capital into Malaysian government co-investment projects.
• Potential revenue acceleration through strategic alliances, mergers, or acquisitions facilitated by the Companys investment banking advisor.
• Active evaluation of cryptocurrency and blockchain-based financial infrastructure as a treasury diversification tool, pending completion of internal legal and compliance reviews.
• The company will have to close above the minimum bid price of $1 for a total of 10 trading days from the market effective date to regain compliance.

Key Dates

Keywords

BioNexus Gene Lab Corp, financial results, Nasdaq compliance, digital health, molecular diagnostics, blockchain, Chemrex, MRNA Scientific, reverse stock split, corporate governance, Ethereum, treasury strategy, liquid biopsy, chemical raw materials